BEDFORD, Mass.--(BUSINESS WIRE)--Cambridge Heart, Inc. (OTCBB-CAMH) announced today the presentation of a multi-center, prospective study during the Late-Breaking Clinical Trials session of the American College of Cardiology Scientific meeting in New Orleans assessing the utility of Microvolt T-Wave Alternans™ (MTWA), using the CH2000 or HearTwave system, in predicting risk of sudden death among patients with non-ischemic cardiomyopathy.
